<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538862</url>
  </required_header>
  <id_info>
    <org_study_id>VICCNCPED1210</org_study_id>
    <nct_id>NCT01538862</nct_id>
  </id_info>
  <brief_title>Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is
      effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one
      course of treatment with the study drug. The course will be 7 days in length. After receiving
      GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug.
      Thirty day follow up can be done via telephone communication with the patient or family.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will be given 10 micrograms per kilogram per day of G-CSF subcutaneously for 6
      consecutive days. On day 7 each patient will be seen and evaluated in the same manner as on
      day 0. Patients or their parents (if children are too young to reliably respond themselves)
      will also be asked to rate the following via a visual analog scale of 1-9- oral pain,
      pruritus, oral pain, swallowing, and overall sense of well-being. A telephone follow-up will
      be conducted on all patients 28 days after G-CSF so as to evaluate if the effect noted on day
      7 was sustained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change of Active Blisters and in Total Blister/Erosion Counts</measure>
    <time_frame>7 days</time_frame>
    <description>Percent change of active blisters and in total blister/erosion counts from baseline to 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surface Area of Nonhealing Erosions</measure>
    <time_frame>7 days</time_frame>
    <description>Change in surface area of one or two nonhealing erosions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Improved Symptomatology</measure>
    <time_frame>28 days</time_frame>
    <description>Overall clinical improvement in symptomatology and/or findings, as assessed by either the patient or parent. This would include decrease in the number and size of blister and erosions, decreased pain, improved comfort of the patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Granulocyte Colony Stimulating Factor (GCSF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor (GCSF)</intervention_name>
    <description>G-CSF 10mcg/kg/d SQ for 7 days</description>
    <arm_group_label>Granulocyte Colony Stimulating Factor (GCSF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each patient must have the diagnosis of severe generalized recessive dystrophic EB
             (formerly known as Hallopeau-Siemens RDEB) confirmed by clinical criteria and either
             of the following:

               1. transmission electron microscopy

               2. immunofluorescence antigenic mapping and type VII collagen monoclonal antibody
                  staining

               3. COL7A1 mutational analysis

        Exclusion Criteria:

          -  The patient must not have a history of squamous cell carcinoma or any internal
             malignancy.

          -  Female patients who are pregnant.

          -  Patients with active signs and symptoms of infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haydar Frangoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Haydar Frangoul</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
          <description>GCSF 10mcg/kg/d SQ for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d SQ for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
          <description>GCSF 10mcg/kg/d SQ for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d SQ for 7 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of Active Blisters and in Total Blister/Erosion Counts</title>
        <description>Percent change of active blisters and in total blister/erosion counts from baseline to 7 days</description>
        <time_frame>7 days</time_frame>
        <population>Time frame was originally entered as 30 days. This was not consistent with the protocol which listed a 7 day time frame for this Outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
            <description>GCSF 10mcg/kg/d subcutaneously for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d subcutaneously for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Active Blisters and in Total Blister/Erosion Counts</title>
          <description>Percent change of active blisters and in total blister/erosion counts from baseline to 7 days</description>
          <population>Time frame was originally entered as 30 days. This was not consistent with the protocol which listed a 7 day time frame for this Outcome</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surface Area of Nonhealing Erosions</title>
        <description>Change in surface area of one or two nonhealing erosions</description>
        <time_frame>7 days</time_frame>
        <population>Time frame was originally entered as 30 days. This was not consistent with the protocol which listed a 7 day time frame for this Outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
            <description>GCSF 10mcg/kg/d subcutaneously for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d subcutaneously for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Surface Area of Nonhealing Erosions</title>
          <description>Change in surface area of one or two nonhealing erosions</description>
          <population>Time frame was originally entered as 30 days. This was not consistent with the protocol which listed a 7 day time frame for this Outcome</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.3" spread="100.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Improved Symptomatology</title>
        <description>Overall clinical improvement in symptomatology and/or findings, as assessed by either the patient or parent. This would include decrease in the number and size of blister and erosions, decreased pain, improved comfort of the patient.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
            <description>GCSF 10mcg/kg/d SQ for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d SQ for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Improved Symptomatology</title>
          <description>Overall clinical improvement in symptomatology and/or findings, as assessed by either the patient or parent. This would include decrease in the number and size of blister and erosions, decreased pain, improved comfort of the patient.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Granulocyte Colony Stimulating Factor (GCSF)</title>
          <description>GCSF 10mcg/kg/d SQ for 7 days
Granulocyte Colony Stimulating Factor (GCSF): G-CSF 10mcg/kg/d SQ for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Haydar Frangoul, MD, MS</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-342-7339</phone>
      <email>Haydar.Frangoul@hcahealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

